NCT06656390 2026-03-06
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors
Shanghai Allink Biotherapeutics Co., Ltd.
Phase 1/2 Recruiting
Shanghai Allink Biotherapeutics Co., Ltd.
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Cancer Commons
Weill Medical College of Cornell University
Singapore General Hospital
University of Colorado, Denver
Canadian Cancer Trials Group
University of Rochester
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Bristol-Myers Squibb
Duke University
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Suzhou Transcenta Therapeutics Co., Ltd.